Eckert & Ziegler to Present at Prestigious J.P. Morgan Healthcare Conference

Eckert & Ziegler SE will participate in the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, 14 January 2026, at the Westin St. Francis in San Francisco, CA, USA. Dr Harald Hasselmann, CEO of Eckert & Ziegler SE, will present the company at 17:15 PST. This participation matters because the J.P. Morgan Healthcare Conference is widely regarded as the largest and most informative healthcare investment symposium globally, attracting thousands of investors, executives, and industry leaders. For Eckert & Ziegler, a company listed on the TecDAX index with shares identified by ISIN DE0005659700, presenting at this event provides a significant platform to communicate its value proposition directly to the investment community.

The implications of this announcement are substantial for stakeholders tracking the radiopharmaceutical and nuclear medicine sectors. Eckert & Ziegler's role as a leading specialist for isotope-related components positions it at the forefront of medical advancements in cancer treatment and diagnostic imaging. By engaging at this high-profile conference, the company signals its ongoing commitment to transparency and investor relations, which can influence market perception and investment decisions. The presentation will be available as an audio livestream on the company's website at https://www.ezag.com/investors/presentations/, ensuring broader accessibility for those unable to attend in person. After the event, the recording will be available for approximately 30 days, extending the reach of the company's messaging.

This event is important as it offers insights into Eckert & Ziegler's strategic direction, operational performance, and future outlook within the rapidly evolving healthcare landscape. With over 1,000 employees, the company's broad range of services and products for the radiopharmaceutical industry—from early development to contract manufacturing and distribution—underscores its integral role in medical innovation. Participation in such conferences often correlates with increased investor attention and potential partnerships, which can drive growth and enhance shareholder value. The original release can be viewed on www.newmediawire.com, providing additional context for the announcement. Ultimately, Eckert & Ziegler's presence at this conference reinforces its industry standing and highlights the critical importance of nuclear medicine technologies in advancing global health outcomes.